R115777, a nonpeptidomimetic farnesyl transferase inhibitor has recently demonstrated a significant antileukemic activity in vivo in acute myeloid leukemia. Multiple myeloma (MM) is a fatal hematological malignancy characterized by an accumulation of long-lived plasma cells within the bone marrow. In the present study, we have investigated the effect of the R115777 on growth and survival of myeloma cells. We have found that R115777 induced (1) a significant and dose-dependent growth inhibition of the three myeloma cell lines tested; and (2) a significant and time-dependent apoptosis. R115777 also induced apoptosis in the bone marrow mononuclear cell population of four MM patients, being almost restricted to the malignant plasma cells. Finally, we have investigated the effect of the R115777 in the Ras/MAPK and JAK/STAT pathways which are implicated in survival and/or proliferation in MM. The phosphorylation of both STAT3 and ERK1/2 induced by IL-6 was totally blocked at 15 M of R115777 and partially blocked when R115777 was used at 10 and 5 M. The induction of apoptosis by R115777 in myeloma cells and its implication in the regulation of JAK/STAT signalling suggest that R115777 might be an interesting therapeutical approach in MM.
Introduction
Multiple myeloma (MM) is characterized by an accumulation of neoplastic long-lived plasma cells (PC) within the bone marrow. Despite intensive therapy with autologous hematopoietic support, MM remains a fatal hematological malignancy. Thus, there is an obvious need for new therapeutic strategies.
1 R115777, a nonpeptidomimetic farnesyl transferase inhibitor (FTI) initially developed to inhibit the growth of Ras transformed cells, shows antiproliferative effects in a wide variety of human tumor cells. 2, 3 Moreover, several ongoing clinical trials have shown some efficacy of R115777 in the treatment of solid tumors and hematologic malignancies particularly in acute myeloid leukemia where preliminary results seem promising. [4] [5] [6] [7] More generally, there is now evidence to indicate that most FTI demonstrate antitumor activity independently of the presence or absence of Ras mutations. 8, 9 Indeed, in addition to Ras proteins, multiple downstream targets appear to be affected by fanesyl transferase inhibition. [10] [11] [12] In MM, the role of IL-6 as the major growth and survival factor is now well established. 13 Commonly, IL-6 can activate the Ras/MAPK and JAK/STAT pathways, 14 which have been implicated in survival and/or proliferation in MM. [15] [16] [17] [18] Thus, the JAK/STAT and Ras/MAPK transduction pathways are two potential therapeutic targets in MM. Furthemore, ras gene mutations are frequently detected (60%) in MM, mainly involving K-ras. 19 In this study, we have investigated the effect of the R115777 in both human myeloma cell lines and primary myeloma cells. Our findings will be discussed in relationship to IL-6 signalling.
Patients and methods

Human myeloma cell lines (HMCLs) and culture conditions
The XG-2 IL-6-dependent HMCL has been previously established in our laboratory and was cultured in the presence of 6 ng/ml of r-IL-6 (Novartis, Basel, Switzerland). The LP-1 HMCL was purchased from DSM (Braunschweig, Germany) and U266 was obtained from the American Type Culture Collection (Rockville, MD, USA). Cells were maintained in RPMI-1640 medium supplemented with 5% fetal calf serum (FCS), 2 mM glutamine, antibiotics (100 IU/ml penicillin and 100 g/ml streptomycin), and 10 M 2-␤-mercaptoethanol.
Patients and cell preparations
Five patients newly diagnosed with MM were included in the current study. All these patients had symptomatic disease and fulfilled the diagnostic criteria of the Southwest Oncology Group. 20 Mononuclear cells were isolated by Ficoll-Hypaque density centrifugation of either bone marrow aspirates or peripheral blood from patients with MM. The percentages of plasma cells (PC) were evaluated by a double immunostaining with CD138 and CD38 mAbs analyzed by flow cytometry.
Monoclonal antibodies (mAbs) and reagents
Anti-phospho-STAT3, anti-phospho-ERK1/2 mAbs were purchased from New England Biolabs (Beverly, MA, USA) and anti-actin mAb from Chemicon International (Temecula, CA, USA). APO 2.7-PE and CD38 APC were from Beckman Coulter (Roissy, France) and Becton Dickinson (Le Pont de Claix, France), respectively.
Farnesyl transferase inhibitor (FTI)
The FTI (R115777) was obtained from Janssen Research Foundation. A solution of 10 mM R115777 was prepared in DMSO. Then the indicated concentrations of R115777 were all prepared from a 1000× stock solution in DMSO.
Proliferation assays
Proliferation assays were performed in 96-well flat bottom microtiter at an initial density of 10 4 cells/well in a final volume of 200 l for 3 days. DNA synthesis was quantified by [ 3 H] thymidine uptake as previously described. 21 
Immunoblot analysis
Cells (4 × 10 6 ) were resuspended in lysis buffer (10 mM TrisHCl pH 7.6, 150 mM NaCl, 5 mM EDTA, 1 mM PMSF, 2 mM Na 3 VO 4 , 1 mM NaF, 2 g/ml aprotinine and 0.5% NP40). After 40 min on ice, lysates were cleared by centrifugation at 12 000 g for 30 min at 4ºC. Protein concentration was measured using bicinchoninic acid (BCA protein assay, Pierce, Rockford, IL, USA). Sixty micrograms of proteins were loaded for each lane. The proteins were separated by 10% SDS-PAGE and then electrotransferred to PVDF membranes. Western blot analysis was performed by standard techniques with ECL detection (Pierce).
Detection of apoptosis
The percentage of apoptotic cells was determined by flow cytometry using the APO 2.7 mAb as described by Koester et al. 22 In MM patients, apoptotic cells were defined by double immunostaining using CD38 APC and APO2.7 PE. Plasma cell population was identified as CD38 bright cells. 2.5 × 10 5 cells were incubated at 4ºC for 20 min with the different mAbs in simple or double-staining in PBS and then washed and fixed in PBS 1% formaldehyde. Flow cytometry analysis was performed on a FACSCalibur using the CELLQuest program (Becton Dickinson).
Results and discussion
The effect of R115777 on myeloma cell growth was examined. This study was performed on three HMCLs presenting with different growth status, ie XG-2, an IL-6 dependent HMCL, U266, a well-characterized IL-6 autocrine HMCL and LP-1, an IL-6-independent HMCL. R115777 totally inhibited D, diagnosis; PB, peripheral blood; BM, bone marrow.
Leukemia
Figure 1
The dose-response curves of R115777 against XG-2, U266 and LP-1. Cell growth inhibition was measured by [ the growth of all 3 HMCLs (Figure 1 ). The IC 50 of R115777 were 50 nM for XG-2, 1.5 M for U266 and 300 nM for LP-1. U266 and LP-1 HMCLs have no Ras mutation and appeared less sensitive to R115777 than XG-2 which bears the 35GϾC substitution in the K-ras gene. 19 However, all cell lines were sensitive to the growth inhibitory effect of R115777 and Ras mutation was not required to inhibit cell proliferation as already reported for a variety of FTI inhibitors. 8, 9 To determine their ability to undergo apoptosis, HMLCs were exposed to 0.5 to 10 M of R115777 for 3 days in their respective culture medium. Pharmacokinetic studies of R115777 in patients have previously shown that concentrations of 0.5 to 10 M of R115777 were in the range of therapeutical concentrations. 3, 4 Apoptosis was monitored daily by APO2.7 staining. Ten micromolars of R115777 induced significant apoptosis (Ն40% of apoptotic cells) in XG-2 and LP-1 after 48 h of treatment and in U266 after 72 h (Figure 2) . Moreover, lower doses of R115777 (0.5 M and
Figure 2
Dose-response curve of apoptosis induced by R115777 on myeloma cell lines. Myeloma cells were cultured as described in Figure 1 . Apoptosis was monitored daily on the basis of Apo2.7 staining. One representative experiment out of three is shown.
Leukemia 5 M) induced a weak but significant apoptosis, reaching 20% to 35% of apoptotic cells in XG-2 and LP1, respectively after 48 h of drug exposure. The findings that all cell lines tested are sensitive to R115777 indicated that the expression of a ras mutation was not necessary for FTI sensitivity as already reported by Karp et al. 6 Of major interest, the presence of high doses of IL-6 (50 ng/ml) in XG-2 culture did not reduce the apoptosis induced by R115777 (result not shown). Finally, total mononuclear cells from bone marrow or blood of five MM patients have been exposed to R115777 for 72 h in the presence of 6 ng/ml of IL-6. Interestingly, the induced apoptosis was mainly restricted to plasma cell population as shown in Figure 3 . Indeed, for patient 1 the percentage of apoptosis was 18% in the non-myeloma cell population whereas it reached 58% in the myeloma cell population at day 3. Finally, R115777 induced apoptosis in all primary myeloma cells with a percentage of apoptotic cells ranging from 47 to 87% at day 3 ( Table 1 ). These results indicated that normal cells were not susceptible to R115777-induced apoptosis under the same conditions that trigger the killing of myeloma cells indicating a difference in survival requirements.
In MM cells, evidence suggests that STAT-3 activation confers a survival advantage. 17 Indeed, in myeloma cells, the JAK/STAT pathway could be more devoted to survival, whereas the Ras/MAP kinase pathway could rather control proliferation. Thus, we investigated the effect of R115777 on STAT3 and ERK1/2 phosphorylation induced by IL-6 ( Figure  4 ). Twelve-hour pretreatment with R115777 induced a dosedependent inhibition of both STAT3 and ERK activation induced by IL-6. The phosphorylation of both STAT3 and ERK1/2 was totally blocked at 15 M and partially blocked when R115777 was used at 10 and 5 M. In agreement with our observation a phase I study in patients with AML and ALL
Figure 3
Flow cytometry measurement of Apo2.7 expression in bone marrow mononuclear cells from MM patient number 1. Mononuclear cells were incubated 48 or 72 h with or without R115777 in RPMI-1640 10% FCS with 6 ng/ml of r-IL-6. Percentage of Apo2.7 expression was indicated in the plasma cell population (CD38 bright positive cells) and in the non-plasma cell population (CD38 weak positive cells).
Figure 4
Immunoblot analysis of STAT3 and ERK1/2 phosphorylation induced by IL-6. Myeloma cells were cultured with or without the indicated concentration of R115777 for 12 h, then stimulated with IL-6 for 10 min. The membrane was hybridized with an anti-phospho-STAT-3 and an anti-phospho-ERK1/2. An anti-actin mAb was used as a control for protein loading.
has demonstrated that R115777 resulted in ERK dephosphorylation in leukemic marrow samples. 6 In myeloma cells, previous results have shown that inhibition of the JAK/STAT pathway by a JAK2 inhibitor induced a strong apoptosis, 18 whereas the inhibition of the MAPKinase pathway by the U0126 inhibitor did not induce apoptosis (personal data). Also, this suggests that R115777 targets a farnesylated protein that regulates the JAK/STAT pathway and induces apoptosis, and underlines the idea that multiple downstream targets appear to be affected by FTI. Since R115777 block the JAK/STAT pathway induced by IL-6, this result may explain why IL-6 cannot impede R11577-induced apoptosis in myeloma cells.
In conclusion, these results suggest that targeting the JAK/STAT pathway by R115777 even in the presence of high doses of IL-6 could be of major interest in the treatment of MM.
